Int J Psychiatry Clin Pract. 2002;6(4):193-7. doi: 10.1080/136515002761580983.
While efficacy in treatment of the acute phase of schizophrenia is well established for so-called atypical antipsychotics, more data regarding long-term treatment are needed.
In a naturalistic, open-label study, 32 patients were included in order to investigate the efficacy and safety of risperidone over 3 years of treatment; 26 of them were treatment-resistant to the previously used antipsychotic drugs (except clozapine).
At the end of the first year, 20 of these 26 patients showed at least partial improvement. At the end of the third year, 17 patients were still being treated with risperidone. While eight patients were lost to follow-up, six relapsed in spite of good compliance. All the adverse events which occurred during treatment were strictly dose-dependent and disappeared when the dose was lowered to 4 mg daily.
Within the limits of naturalistic studies, it can be concluded that risperidone seemed to be an effective and safe drug for long-term treatment in the majority of our patients. (Int J Psych Clin Pract 2002; 6: 193-197 ).
虽然所谓的非典型抗精神病药物在治疗精神分裂症急性期方面的疗效已得到充分证实，但仍需要更多关于长期治疗的数据。
在一项自然主义、开放性研究中，纳入了 32 名患者，以调查利培酮在 3 年治疗中的疗效和安全性；其中 26 名患者对之前使用的抗精神病药物（氯氮平除外）有治疗抵抗。
在第一年结束时，这 26 名患者中的 20 名至少有部分改善。在第三年末，17 名患者仍在接受利培酮治疗。虽然有 8 名患者失访，但有 6 名患者尽管依从性良好，但仍复发。治疗期间发生的所有不良事件均与剂量严格相关，当剂量降至每天 4 毫克时，不良事件消失。
在自然研究的范围内，可以得出结论，利培酮似乎是一种有效且安全的药物，可用于大多数患者的长期治疗。（Int J Psych Clin Pract 2002; 6: 193-197）。
